Premium
The Effects of Platelet‐Rich Plasma on Halting the Progression in Porcine Intervertebral Disc Degeneration
Author(s) -
Cho Hongsik,
Holt David C.,
Smith Richard,
Kim SongJa,
Gardocki Raymond J.,
Hasty Karen A.
Publication year - 2016
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/aor.12530
Subject(s) - aggrecan , intervertebral disc , extracellular matrix , matrix metalloproteinase , degeneration (medical) , microbiology and biotechnology , matrix (chemical analysis) , platelet rich plasma , chemistry , growth factor , pathology , immunology , medicine , anatomy , platelet , biology , biochemistry , osteoarthritis , chromatography , articular cartilage , alternative medicine , receptor
Disc degeneration and the subsequent herniation and/or rupture of the intervertebral disc ( IVD ) are due to a failure of the extracellular matrix of the annulus to contain the contents of the nucleus. This results from inadequate maintenance of the matrix components as well as the proteolytic activity of matrix metalloproteinases ( MMP s) that degrade matrix molecules. Arresting progression of disc degeneration in the annulus holds greater clinical potential at this point than prevention of its onset in the nucleus. Therefore, in this study, we have therapeutic aims that would decrease levels of the cytokines and growth factors that indirectly lead to disc degeneration via stimulating MMP and increase levels of several beneficial growth factors, such as transforming growth factor‐β, with the addition of platelet‐rich plasma ( PRP ) that would stimulate cell growth and matrix synthesis. For this study, we attempted to address these imbalances of metabolism by using tumor necrosis factor‐α treated annulus fibrosus cells isolated from porcine IVD tissue and incubating the cells in a growth factor rich environment with PRP . These results indicate that the PRP in vitro increased the production of the major matrix components (type II collagen and aggrecan) and decreased the inhibitory collagenase MMP ‐1. This application will address a therapeutic approach for intervening early in the degenerative process.